Enable JavaScript to ensure website accessibility
Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023

Company anticipates current cash levels sufficient to reach breakeven NEW HAVEN, CT, Globenewswire – (October [...]

Precipio Continues to Sign New HemeScreen™ Customers

New customer orders received in Q3 exceed $1M annualized revenue NEW HAVEN, CT, Globenewswire – [...]

Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven

Higher pathology revenues and lower cost structure drive down product revenue breakeven point from $8M [...]

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

Company announces 1-for-20 reverse stock split NEW HAVEN, CT – (September 21, 2023) – Specialty [...]

Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan

Company continues to make strides towards profitability NEW HAVEN, CT, Globenewswire – (September 13, 2023) – [...]

Precipio Announces Q2-2023 Shareholder Update Call

Conference Call to be held on August 17, 2023 at 5:00 PM EST NEW HAVEN, [...]

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

Advanced panel already generating six-figure pre-orders NEW HAVEN, CT, Globenewswire – (August 8, 2023) – Specialty [...]

Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven

Revenue growth and customer pipeline advance the Company towards breakeven NEW HAVEN, CT, Globenewswire – [...]

Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023

Revenue growth and customer pipeline advance the Company towards breakeven NEW HAVEN, CT, Globenewswire – [...]

Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology

New panel will enable rapid, precise genetic profiling of patients with deadly disease NEW HAVEN, [...]